Tang et al. in 2022 showed that the distant metastases (stage IV in NSCLC) have been characterized by immunosuppression (low level of CD8+ T cells) and immune evasion (high level of PD-L1) [33]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.